BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wu X, Tian F, Su M, Wu M, Huang Y, Hu L, Jin L, Zhu X. BF211, a derivative of bufalin, enhances the cytocidal effects in multiple myeloma cells by inhibiting the IL-6/JAK2/STAT3 pathway. International Immunopharmacology 2018;64:24-32. [DOI: 10.1016/j.intimp.2018.08.016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Kaur S, Bansal Y, Kumar R, Bansal G. A panoramic review of IL-6: Structure, pathophysiological roles and inhibitors. Bioorg Med Chem 2020;28:115327. [PMID: 31992476 DOI: 10.1016/j.bmc.2020.115327] [Cited by in Crossref: 49] [Cited by in F6Publishing: 54] [Article Influence: 24.5] [Reference Citation Analysis]
2 Xu Y, Feng X, Zhou Q, Jiang W, Dai Y, Jiang Y, Liu X, Li S, Wang Y, Wang F, Li A, Zheng C. Novel Small Molecular Compound AE-848 Potently Induces Human Multiple Myeloma Cell Apoptosis by Modulating the NF-κB and PI3K/Akt/mTOR Signaling Pathways. Onco Targets Ther 2020;13:13063-75. [PMID: 33376355 DOI: 10.2147/OTT.S270090] [Reference Citation Analysis]
3 Cheng CS, Wang J, Chen J, Kuo KT, Tang J, Gao H, Chen L, Chen Z, Meng Z. New therapeutic aspects of steroidal cardiac glycosides: the anticancer properties of Huachansu and its main active constituent Bufalin. Cancer Cell Int 2019;19:92. [PMID: 31011289 DOI: 10.1186/s12935-019-0806-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
4 Nahi H, Kashif M, Klimkowska M, Karvouni M, Wallblom A, Gran C, Hauenstein J, Frengen N, Gustafsson C, Afram G, Uttervall K, Lund J, Månsson R, Wagner AK, Alici E. Low dose venetoclax as a single agent treatment of plasma cell malignancies harboring t(11;14). Am J Hematol 2021;96:925-33. [PMID: 33901326 DOI: 10.1002/ajh.26207] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Lu D, Sun L, Li Z, Mu Z. lncRNA EZR‑AS1 knockdown represses proliferation, migration and invasion of cSCC via the PI3K/AKT signaling pathway. Mol Med Rep 2021;23:76. [PMID: 33236153 DOI: 10.3892/mmr.2020.11714] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Yang L, Zhou F, Zhuang Y, Liu Y, Xu L, Zhao H, Xiang Y, Dai X, Liu Z, Huang X, Wang L, Zhao C. Acetyl-bufalin shows potent efficacy against non-small-cell lung cancer by targeting the CDK9/STAT3 signalling pathway. Br J Cancer 2021;124:645-57. [PMID: 33122847 DOI: 10.1038/s41416-020-01135-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
7 Zhou J, Zhou P, Zhang Y, Wang G, Fan Z. Signal Pathways and Markers Involved in Acute Lung Injury Induced by Acute Pancreatitis. Dis Markers 2021;2021:9947047. [PMID: 34497676 DOI: 10.1155/2021/9947047] [Reference Citation Analysis]
8 Fang K, Zhan Y, Zhu R, Wang Y, Wu C, Sun M, Qiu Y, Yuan Z, Liang X, Yin P, Xu K. Bufalin suppresses tumour microenvironment-mediated angiogenesis by inhibiting the STAT3 signalling pathway. J Transl Med 2021;19:383. [PMID: 34496870 DOI: 10.1186/s12967-021-03058-z] [Reference Citation Analysis]
9 Gu C, Wang Y, Zhang L, Qiao L, Sun S, Shao M, Tang X, Ding P, Tang C, Cao Y, Zhou Y, Guo M, Wei R, Li N, Xiao Y, Duan J, Yang Y. AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma. J Exp Clin Cancer Res 2022;41:11. [PMID: 34991674 DOI: 10.1186/s13046-021-02220-1] [Reference Citation Analysis]
10 Piao X, Zou Y, Sui X, Liu B, Meng F, Li S, Zhang Q, Ma C, Wu T. Hydrostatin-SN10 Ameliorates Pancreatitis-Induced Lung Injury by Affecting IL-6-Induced JAK2/STAT3-Associated Inflammation and Oxidative Stress. Oxid Med Cell Longev 2019;2019:9659757. [PMID: 31827715 DOI: 10.1155/2019/9659757] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
11 Pop V, Parvu A, Craciun A, Farcas AD, Tomoaia G, Bojan A. Modern markers for evaluating bone disease in multiple myeloma (Review). Exp Ther Med 2021;22:1329. [PMID: 34630683 DOI: 10.3892/etm.2021.10764] [Reference Citation Analysis]
12 Zhu F, Jiang D, Zhang M, Zhao B. 2,4-Dihydroxy-3'-methoxy-4'-ethoxychalcone suppresses cell proliferation and induces apoptosis of multiple myeloma via the PI3K/akt/mTOR signaling pathway. Pharm Biol 2019;57:641-8. [PMID: 31564190 DOI: 10.1080/13880209.2019.1662814] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]